TriangleBortezomib (NCT03136146)
Bortezomib trial for Recurrent Acute Lymphoblastic Leukemia (NCT03136146). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for people older than fifteen with relapsed or refractory acute lymphoblastic leukemia, lymphoblastic lymphoma, Burkitt leukemia or lymphoma, or double-hit leukemia or lymphoma. Philadelphia-positive leukemia is eligible for phase two.
The idea: multi-drug chemotherapy attacks cancer growth, with bortezomib blocking protein breakdown. Treatment also includes an antibody and blood-cell support. Induction may be repeated if needed, followed by up to five consolidation courses. Researchers measure remission, side effects, and survival.
This phase 2 study plans 42 patients. Maro Ohanian leads at MD Anderson in Houston, the sole recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.